Company profile: Boundless Bio
1.1 - Company Overview
Company description
- Provider of precision oncology therapeutics and diagnostics targeting extrachromosomal DNA (ecDNA) in aggressive cancers, including BBI-355 (oral CHK1 inhibitor for ecDNA-enabled oncogene amplified cells), BBI-825 (oral RNR inhibitor disrupting ecDNA assembly and repair), the Spyglass platform to identify and validate druggable targets in ecDNA-cancer cells, and ECHO to detect ecDNA from routine clinical next-generation sequencing data.
Products and services
- Spyglass Platform: Proprietary platform that identifies and validates druggable targets in ecDNA-cancer cells, enabling creation of ecDNA-directed therapies through target discovery and validation workflows
- BBI-355: Oral, selective inhibitor of checkpoint kinase 1 (CHK1) designed to treat ecDNA-enabled oncogene-amplified cancer cells by exploiting elevated replication stress
- BBI-825: Oral, selective inhibitor of ribonucleotide reductase (RNR) aimed at disrupting ecDNA assembly and repair in cancer cells reliant on ecDNA
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Boundless Bio
TAE Life Sciences
HQ: United States
Website
- Description: Provider of biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT), offering the Alphabeam compact hospital-use tandem accelerator neutron source, BNCT combining boron-10 drugs and neutron beams to selectively destroy cancer cells, and TC220, a boronated amino acid analog targeting cancers including GBM, breast, and melanoma; the only company with comprehensive target drug and neutron technology product.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TAE Life Sciences company profile →
Prelude Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule cancer therapies and precision antibody-drug conjugates, including PRT3789, a selective SMARCA2 degrader for SMARCA4-deficient tumors; PRT2527, a highly selective CDK9 inhibitor in Phase 1; PRT3645, a next-generation CDK4/6 inhibitor in preclinical studies; and ADCs developed with AbCellera.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prelude Therapeutics company profile →
Xcovery
HQ: United States
Website
- Description: Provider of low-toxicity, molecular-targeted oral cancer therapeutics, including Ensartinib for ALK-positive non-small cell lung cancer and Vorolanib, a VEGFR/PDGFR tyrosine kinase inhibitor for solid tumors such as renal cell carcinoma. Conducts clinical trials, seeks partnerships to launch Ensartinib globally and advance Vorolanib in combination therapy, and offers patient information and support resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xcovery company profile →
Adaptive Biotechnologies
HQ: United States
Website
- Description: Provider of immune system-based products to diagnose and treat disease, including clonoSEQ, an FDA-cleared service for detecting and monitoring minimal residual disease in bone marrow from patients with certain blood cancers; immunoSEQ, a tool for profiling and monitoring the adaptive immune response, aiding research across multiple disease areas; and T-Detect COVID, a diagnostic using T cell markers, authorized for emergency use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptive Biotechnologies company profile →
PACT Pharma
HQ: United States
Website
- Description: Provider of personalized adoptive T cell therapies designed for the eradication of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PACT Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Boundless Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Boundless Bio
2.2 - Growth funds investing in similar companies to Boundless Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Boundless Bio
4.2 - Public trading comparable groups for Boundless Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →